Oncolytics Biotech (ONCY) Other Accumulated Expenses (2018 - 2025)

Oncolytics Biotech (ONCY) has 7 years of Other Accumulated Expenses data on file, last reported at $123528.0 in Q3 2025.

• On a quarterly basis, Other Accumulated Expenses rose 7.33% year-over-year to $123528.0 in Q3 2025; TTM through Sep 2025 was $123528.0, a 7.33% increase from a year earlier, with the FY2024 full-year figure at $1.1 million, up 357.19% from the prior year.
• Other Accumulated Expenses for Q3 2025 stood at $123528.0, down from $708721.7 in the prior quarter.
• Over the last five years, Other Accumulated Expenses for ONCY reached as high as $1.2 million in Q4 2024 and fell as low as $69371.5 in Q3 2023.
• Historically, Other Accumulated Expenses has averaged $422097.0 across 4 years, with a median of $261560.0 in 2021.
• Across the five-year window, Other Accumulated Expenses jumped 374.95% in 2024 and fell 23.01% in 2025, its largest moves.
• Year by year, Other Accumulated Expenses stood at $279254.3 in 2021, then declined by 12.67% to $243865.8 in 2023, then soared by 374.95% to $1.2 million in 2024, then tumbled by 89.33% to $123528.0 in 2025.
• Per Business Quant data, the three most recent Other Accumulated Expenses figures were $123528.0 in Q3 2025, $708721.7 in Q2 2025, and $369365.7 in Q1 2025.